In AL #Amyloidosis, we are no longer in an era of ~30% early mortality! New data by George Mellgard shows 6 mo early mortality ~11% in 335 pts with Dara-VCd/Dara-Vd (44% stage IIIa/IIIb) Predictors of EM-Age, ECOG/NYHA, NT-proBNP & absence of t(11;14)! #ASH24

#ASH24 Excellent work by Heloise Cheruvalath Meera Mohan et al showing value of IVIG with BCMA-targeted bsAbs in #MMsm. 🤯 OS benefit?? Likely other confounders, e.g. evolving ⬆️ IVIG use vs ⬇️ pandemic lethality... ... But clearly the days of waiting for IVIG ≤400 are gone!

#ASH24 MajesTEC-4! Zamagni et al: Safety run-in for tec + len maintenance after ASCT. First time we're seeing bsAb maintenance data in #MMsm 👏 Bottom line: it works! But important to see: Tec as maintenance is same as tec in RRMM: CRS and infections can happen. Use IVIG!

Tec-Len safety run in as post-ASCT maintenance #ASH24 #mmsm #mmMRD - Convenient dosing schedule - Nearly everyone got significant neutropenia (94% G3+) - CRS rates are lower overall in this low-disease burden setting (40-50%)

Now we are asking the correct q in the correct setting …..

More on teclistamab....this time with pomalidomide and daratumumab. Here we see a signal for very high infection rates, including grade ¾ (despite IVIG). Questions: Is this infection risk because of prior therapies increasing risk of infection? Or just longer follow-up? Is

Subgroup analysis of AURIGA: Dara-Len vs Len for pts with MRD+ post-ASCT. I like the breakdown re: benefit in high-risk disease (however you want to define it!) - Dara-R benefit seems to extend to all patients regardless of risk; perhaps particularly so for patients with 1

The coolest ASH presentation 😎

AQUILA: Daratumumab x 3 years vs. active surveillance for smoldering myeloma - All patients had advanced imaging (CT/PET/MRI during screening and yearly) - Primary endpoint: PFS per IMWG SLiM-CRAB criteria - Secondary endpoints: included OS (see image for stats) - Only about 40%

#ASH24 #mmsm ASH Oral: amyloidosis MRD -ve in AL amyloidosis is associated with better outcomes, no correlation between MRD status and cardiac or renal responses (it is important in heme responses) - it may be related to earlier assessment since organ function

#ASH24 excellent work by my Fred Hutch Cancer Center colleague Danai Dima on behalf of the US #MMsm consortium 👏 Prior BCMA therapy before BCMA CAR-T: same principle as CARTITUDE-2C, but much larger RW data. Small n, but BCMA bsAb ➡️ CAR-T doing much worse than BCMA ADC ➡️ CAR-T.

#ASH24 #mmsm ASH Oral amyloidosis: Final update of ANDROMEDA A great study with OS improvement (despite more than 70% of pts in control arm received Dara based regimen) This is coupled with better organ responses #ASHKudos for an excellent study with OS benefit

Even in the best case scenario (>9 months), still leaves something to be desired. Is switching target after BCMA CAR T a better move?

BCMA CART for AL Amyloidosis! #ash24

#ASH24 and the best for last! Our fearless US #MMsm consortium leader #DorisHansen presenting the most sophisticated analysis of cilta-cel vs ide-cel in RW practice I’ve ever seen! Yes, an RCT will be ideal - but will never happen this decade. So what do our current data show?

#BCL2 inhibitors in #myeloma and #Amyloidosis? Yes please! Lisaftoclax in #RRMM Jack Khouri Cleveland Clinic MD #ASH24

#ASH24 #mmsm ASH Oral myeloma: Anti-BCMA/GPRC5D Bispecific CAR T-Cells in Patients with Refractory and Relapsed Multiple Myeloma with Extramedullary Disease Short follow up with low n of pts- median follow up of only 6 months It is unclear that targeting both

#ASH24 #mmsm ASH Oral myeloma: MagnetisMM-20 Carf+Elra low no. of pts Responses are high (ORR 100%) 1 death with COVID-19 Most infections were G1 and G2 (G3 or higher of 17%) CMV re-activation in 50% of pts Seems to have nice synergistic effect with Carf and

CONGRESS | #ASH24 | POSTER Caitlin Costello Caitlin Costello, MD, UCSD Moores Cancer Center, shares results from the optimized lymphodepletion cohort (N = 21) of a phase I study of P-BCMA-ALLO1, a BCMA-directed CAR-T in RRMM. P-BCMA-ALLO1 demonstrates a promising ORR and favorable

Delayed neurotoxicity poster with my mentor Ajai Chari